Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: Twelve-month results

Retina

Volumn 29, Issue 6, 2009, Pages 740-749

  Gharbiya, Magda ^a   Allievi, Francesca ^a   Recupero, Vincenzo ^a   Martini, Delia ^a   Mazzeo, Luigi ^a   Gabrieli, Corrado Balacco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE EXAMINATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; INTRAOCULAR PRESSURE; MALE; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; RETINA DEGENERATION; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; RETINA NEOVASCULARIZATION; RETINAL ANGIOMATOUS PROLIFERATION; SIDE EFFECT; VISUAL ACUITY; VITREOUS HEMORRHAGE;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COLORING AGENTS; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INDOCYANINE GREEN; INJECTIONS; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL DETACHMENT; RETINAL NEOVASCULARIZATION; RETINAL PIGMENT EPITHELIUM; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 67749102136     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181a0be1d     Document Type: Article

References (33)

1. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001; 21:416-434.
2. Gass JDM, Agarwal A, Lavina AM, Tawansy KA. Focal inner retinal hemorrahages in patients with drusen: an early sign of occult choroidal neovascularization and chorioretinal anastomosis. Retina 2003;23:741-751.
3. Freund KB, Ho I, Barbazetto IA, et al. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina 2008;28:201-211.
4. Yannuzzi LA, Freund KB, Takahashi BS. Review of retinal angiomatous proliferation of type 3 neovascularization. Retina 2008;28:375-384.
5. Gass JD. Stereoscopic Atlas of Macular Diseases. 4th ed. St. Louis: C.V. Mosby;1997:26-30.
6. Gross NE, Aizman A, Brucker A, et al. Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina 2005;25:713-718.
7. Johonson TM, Glaser BM. Focal laser ablation of retinal angiomatous proliferation. Retina 2006;26:756-772.
8. Bottoni F, Massaccesi A, Cigada M, et al. Treatment of retinal angiomatous proliferation in age-related macular degeneration. Arch Ophthalmol 2005;123:1644-1650.
9. Krebs I, Binder S, Stolba U. A new treatment regimen in combined intravitreal injection of triamcinolone acetonide and photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2006;244:863-867.
10. Freund KB, Klais CM, Eandi CM, et al. Sequenced combined intravitreal triamcinolone and indocyanine green angiographyguided photodynamic therapy for retinal angiomatous proliferation. Arch Ophthalmol 2006;124:487-492.
11. Klais CM, Eandi CM, Ober MD, et al. Anecortave acetate treatment for retinal angiomatous proliferation. Retina 2006; 26:773-779.
12. Shimada H, Mori R, Arai K, Kawamura A, Yuzawa M. Surgical excision of neovascularization in retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2005;243: 519-524.
13. Joeres S, Heussen FMA, Treziak T, Bopp S, Joussen A. Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2007;245:1597-1602.
14. Meyerle CB, Freund KB, Iturralde D, et al. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. Retina 2007;27:451- 457.
15. Ghazi NG, Knape RM, Kirk TQ, Tiedeman JS, Conway BP. Intravitreal bevacizumab (Avastin) treatment of retinal angiomatous proliferation. Retina 2008;28:689-695.
16. Slakter JS, Yannuzzi LA, Schneider U, et al. Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. Ophthalmology 2000;107:742-754.
17. Boscia F, Battaglia Parodi M, Furino C, et al. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2006;244:1224-1232.
18. Krebs I, Krepler K, Stolba U, Goll A, Binder S. Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone. Graefes Arch Clin Exp Ophthalmol 2008;246:237-243.
19. Koizumi H, Iida T, Saito M, Nagayama D, Maruko I. Choroidal circulatory disturbances associated with retinal angiomatous proliferation on indocyanine green angiography. Graefes Arch Clin Exp Ophthalmol 2008;246:515-520.
20. Shimada H, Kawamura A, Mori R, Yuzawa M. Clicopathological findings of retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2007;245:295-300.
21. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269.
22. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390.
23. Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina 2008; 28:675-681.
24. Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008;92:356-360.
25. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008;145:249-256.
26. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-1185.
27. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006; 142:162-164.
28. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006;26:512-518.
29. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:270-274.
30. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26:257-261.
31. Kaempf S, Johnen S, Salz AK, Weinberger A, Walter P, Thumann G. Effects of bevacizumab (Avastin) on retinal cells in organotypic culture. Invest Ophthalmol Vis Sci 2008;49: 3164-3171.
32. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al; Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87.
33. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;335:1419-1431.